Enobosarm Kev Points
- Mild/Moderate Anabolic Effect
- Mild HPTA Suppression
- Mild Hepatotoxicity
- Mild/Moderate Lipid Changes
- Furthest along in Human Trials
Enobosarm was first described in 2001, in a U.S. patent filed by The University of Tennessee Research Corporation. The drug was placed under development by GTx Inc., a U.S. biotechnology company shortly after. In 2007, Merck took a stake in GTx, in a deal that was said to be worth in excess of $500 million. The two companies set out to jointly develop enobosarm as a drug product. In 2010, however, Merck and GTx parted ways. GTx regained control over enobosarm though, and continues its development track with the drug. To that effect, it has since entered a series of Phase I, II, and III clinical trials in the United States.
In 2013, GTx announced that two Phase III clinical trials on the use of enobosarm for treating muscle wasting in patients with cancer ended unsuccessfully. It appears that although the drug increased lean muscle mass, the study did not meet other pre-determined endpoints involving markers of strength. GTx has reportedly decided to stop pursuing the drug in the U.S. for muscle wasting applications, citing a difficult regulatory environment. However, they do appear committed to further developing this agent as a pharmaceutical. At this time, clinical trails are ongoing for the treatment of breast cancer and stress urinary incontinence.
Enobosarm is on the WADA banned substance list, and is detectable in doping controls. The FDA and GTx have also taken note of the abundant availability of this investigatory drug on the sports nutrition market, and are reportedly working together to curb illegal sales.
Structural Characteristics of Enobosarm
Enobosarm is an aryl-propionamide-derived SARM. It is close in structure to bicalutamide, an anti-androgen. The chemical name of enobosarm is [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide]. It displays high oral bioavailability, and a half-life estimated to be 14-16 hours.
How is Enobosarm Supplied
Enobosarm is not available as a pharmaceutical product. Standard dosage information is currently unavailable. Gray market preparations commonly contain 25mg/ml when in liquid suspension, and 10 mg per capsule in oral products.
Enobosarm is an unapproved new drug. A thorough understanding of its safety and propensity for side effects in humans is lacking at this time. However, this drug has been subject to extensive clinical trials in the United States. As such, there is a body of safety data to review.
Enobosarm Side Effects
In clinical studies with enobosarm, the drug was generally well tolerated.The most common side effects at a 3 mg per day dose were nausea (4.2%), headache (20.8%), fatigue (8.3%), diarrhea (8.3%), pharyngolaryngeal pain (12.5%), back pain (12.5%), and pain in the extremities (4.2%). The drug also elevated serum alanine aminotransferase (ALT) levels in roughly 20% of patients, which is a marker of liver stress. Though ALT values exceeded normal in some cases, this rarely necessitated drug discontinuance. Liver enzymes should be monitored during use.
Similar to anabolic/androgenic steroids, enobosarm also suppresses HDL (good) cholesterol. This was reduced by 27% in study participants taking 3 mg. Likewise; the HDL/LDL ratio was significantly (negatively) impacted. However, there was also a tendency for reduced serum triglyceride levels, and lipid values of patients commonly remained within a normal (low cardiovascular risk) category. The potential impact of these changes on cardiovascular disease risk is unclear.
Many of the side effects of enobosarm do appear to be dose dependent. For example, at 9 mg per day the most common side effects were nausea (31%), fatigue (18%), and pain in the extremities (13%). These appeared with much higher frequency than with the 3 mg dose. The "mild" nature of this drug with regard to general side effects is likely to change as the dosage is escalated beyond the intended therapeutic range.
Suppressed testosterone was not a significant issue in clinical trials with enobosarm.This drug appears to weakly influence the HPTA in therapeutic doses. However, this is sometimes noted in anecdotal reports from the fitness community, where much higher doses are common. This may reflect dose-dependency in this area as well. In some cases, HPTA suppression during use may necessitate a post-cycle therapy program.
Visual disturbances such as night blindness and/or yellowing tint to the vision, which are common with Andarine, are much less frequently reported with enobosarm. These do transiently appear in some users according to anecdotal reports, however. As such, this side effect cannot be completely excluded. Although the visual side effects of SARMsare poorly understood, they typically do resolve on their own shortly after the drug is discontinued.
Enobosarm is given orally. This substance has not been approved for use in humans. Prescribing guidelines are unavailable. During clinical studies, it was most often administered at a dosage of 3 mg, 9 mg, or 18 mg per day.
When used for physique- or performance-enhancing purposes, enobosarm is commonly used at a dosage of 10-30 mg, which is given once per day. Women usually take lower doses than men, usually opting for the low end of the range. Cycles usually last 4-8 weeks. The results from its use are typically characterized by moderate gains in lean mass, which is accompanied by measurable fat loss and a distinct strength increase. The effects are often qualitatively and quantitatively compared to a milder oral anabolic, such as oxandrolone or stanozolol.
It is typically advised to taper-up the dosage of enobosarm, so that the user becomes accustomed to the effects of the drug. This usually involves beginning with a 10 mg daily dose. This is increased by 5 mg every 7 days, until a comfortable dosage level is established.
Enobosarm is not available as a prescription drug product. It is sold exclusively as a "research compound" or gray market supplement. Note that the quality of gray market products can be difficult to assure.
Wlliam Llewellyn (2017) - Anabolics